Total amount: € 0,00
HOW TO ORDER
A Journal on Endocrine System Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Minerva Endocrinologica 2011 June;36(2):117-21
Efficacy of low and high fixed dose radioactive iodine therapy in patients with toxic nodular goiter
Sonmez B. 1, Erem C. 2, Dogan I. 1, Ersoz H. O. 2, Sonmez M. 3 ✉
1 Department of Nuclear Medicine, Karadeniz Technical University, School of Medicine, Trabzon, Turkey;
2 Department of Endocrinologyand Metabolism, Karadeniz Technical University, School of Medicine, Trabzon, Turkey;
3 Department of Hematology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey;
AIM: The efficacy of low and high fixed dose radioactive iodine (RAI) therapy in patients with toxic nodular goiter was investigated.
METHODS: Ninety-three patients (25 males, 68 females) were included into the study (32 patients with toxic adenoma, 61 patients with toxic multinodular goiter). Patients were treated with a fixed dose of 370 MBq (10 mCi) or 740 MBq (20 mCi) RAI. The average follow-up period was 17±10 months.
RESULTS: The overall cure rate (eutyhroidism and hypothyroidism) was 81% in patients treated with 740 MBq RAI and 51% in patients treated with 370 MBq RAI (p<0.05). RAI therapy with a dose of 370 MBq and 740 MBq provided the cure in 73% and 91% of the patients with toxic adenoma and 42% and 76% of the patients with toxic multinodular goiter, respectively. No significant difference for gender was observed. Hypothyroidism developed in 4 and 15 patients with a dose of 370 MBq and 740 MBq RAI, respectively.
CONCLUSION: A dose of 740 MBq RAI was found to be more effective for the treatment of toxic nodular goiter as compared to a dose of 370 MBq RAI.